2,032 reports of this reaction
4.3% of all LINEZOLID reports
#2 most reported adverse reaction
THROMBOCYTOPENIA is the #2 most commonly reported adverse reaction for LINEZOLID, manufactured by Hp Halden Pharma AS. There are 2,032 FDA adverse event reports linking LINEZOLID to THROMBOCYTOPENIA. This represents approximately 4.3% of all 47,534 adverse event reports for this drug.
Patients taking LINEZOLID who experience thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOCYTOPENIA is moderately reported among LINEZOLID users, representing a notable but not dominant share of adverse events.
In addition to thrombocytopenia, the following adverse reactions have been reported for LINEZOLID:
The following drugs have also been linked to thrombocytopenia in FDA adverse event reports:
THROMBOCYTOPENIA has been reported as an adverse event in 2,032 FDA reports for LINEZOLID. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOCYTOPENIA accounts for approximately 4.3% of all adverse event reports for LINEZOLID, making it one of the most commonly reported side effect.
If you experience thrombocytopenia while taking LINEZOLID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.